688266 泽璟制药
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-7.775-9.549-23.293-46.775-32.053
总资产报酬率 ROA (%)-3.105-4.679-12.231-26.789-24.272
投入资产回报率 ROIC (%)-3.546-5.313-14.257-33.181-28.859

边际利润分析
销售毛利率 (%)90.40493.05992.44191.34696.707
营业利润率 (%)-16.305-29.091-77.058-160.618-241.145
息税前利润/营业总收入 (%)-20.764-34.567-81.244-165.924-262.516
净利润/营业总收入 (%)-16.109-28.201-76.373-160.601-242.693

收益指标分析
经营活动净收益/利润总额(%)128.959125.086131.168107.252109.426
价值变动净收益/利润总额(%)-1.064-4.423-4.910-1.349-2.752
营业外收支净额/利润总额(%)1.5840.0030.4350.4911.312

偿债能力分析
流动比率 (X)1.8501.8762.2201.7723.691
速动比率 (X)1.7211.7422.1231.6363.555
资产负债率 (%)61.87058.31143.03052.79728.230
带息债务/全部投入资本 (%)42.53638.95432.74934.8248.893
股东权益/带息债务 (%)101.266123.730192.701165.078936.788
股东权益/负债合计 (%)61.63071.567131.43086.183242.721
利息保障倍数 (X)4.9486.31421.10836.77014.452

营运能力分析
应收账款周转天数 (天)73.15882.55988.55990.121117.952
存货周转天数 (天)846.8801,429.2071,292.9411,038.1892,154.996